Abstract
Background
Ruboxistaurin, a specific inhibitor of the ′1 and ′2 isoforms of protein kinase C, is currently in clinical development for the treatment of several diabetic microvascular complications. The major metabolite, N-desmethyl ruboxistaurin (metabolite 338522), is equipotent in its inhibitory activity. The elimination of ruboxistaurin and its metabolites is primarily through bile and the faecal route, with urinary excretion constituting only a minor route.
Objective
To assess the effects of chronic renal insufficiency on the pharmacokinetics of ruboxistaurin and metabolite 338522.
Methods
Six healthy subjects (creatinine clearance >80 mL/min/1.73m2) and six end-stage renal disease (ESRD) subjects requiring long-term haemodialysis were studied. All subjects received a single oral dose of ruboxistaurin 32mg followed by serial blood sampling up to 72 hours. ESRD subjects underwent haemodialysis approximately 58 hours after dosing, with blood samples obtained immediately before and after dialysis.
Results
No differences were observed in the pharmacokinetic parameters (area under the plasma concentration-time curve from time zero to infinity [AUCα], maximum plasma concentration [Cmax] and elimination half-life [t1/2]) of ruboxistaurin and metabolite 338522 between healthy and ESRD subjects Plasma concentrations of ruboxistaurin were below the lower limit of quantification by the time of haemodialysis. The predicted post-dialysis plasma concentrations of metabolite 338522 were not statistically different from the observed values (p = 0.163). Ruboxistaurin was well tolerated in both groups of subjects.
Conclusion
These results indicate that the kidney is not an important route of metabolism or excretion for ruboxistaurin and metabolite 338522. Based on the pharmacokinetic and tolerability findings, no formal dosage adjustment of ruboxistaurin should be required for patients with any degree of renal impairment who are undergoing haemodialysis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jirousek MR, Gillig JR, Gonzalez CM, et al. (S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cβ. J Med Chem 1996 Jul; 39(14): 2664–71
Aiello LP. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Opthalmol 2002 Dec; 47 Suppl. 2: S263–9
Tuttle KR, Anderson PW. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Am J Kidney Dis 2003 Sep; 42(3): 456–65
Engel GL, Farid NA, Faul MM, et al. Salt form selection and characterization of ruboxistaurin mesylate monohydrate. Int J Pharm 2000 Apr 5; 198(2): 239–47
Tesfamariam B, Brown ML, Deykin D, et al. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest 1990 Mar; 85(3): 929–32
Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 1992 Nov; 89(22): 11059–63
Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996 May; 272(5262): 728–31
Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997 Sep; 46(9): 1473–80
Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999 Oct; 48(10): 2090–5
Nonaka A, Kiryu J, Tsujikawa A, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal micro-circulation of diabetic rats. Invest Ophthalmol Vis Sci 2000 Aug; 41(9): 2702–6
Koya D, Jirousek MR, Lin YW, et al. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997 Jul; 100(1): 115–26
Molecule of the month: ruboxistaurin mesilate hydrate. Drug News Perspect 2003 Dec; 16(10): 691
Ring BJ, Gillespie JS, Binkley SN, et al. The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450. Drug Metab Dispos 2002 Sep; 30(9): 957–61
Demolle D, de Suray JM, Vandenhende F, et al. LY333531 single escalating oral dose study in healthy volunteers [abstract]. Diabetologia 1998; 41 Suppl. 1: A283
Burkey JL, Campanale KM, O’Bannon DD, et al. Disposition of LY333531, a selective protein kinase C beta inhibitor, in the Fischer 344 rat and beagle dog. Xenobiotica 2002 Nov; 32(11): 1045–52
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41
Acknowledgements
This study was financially supported by Eli Lilly and Company, Indianapolis, IN, USA. With the exception of Dr Lau, all authors are employees of Eli Lilly and Company.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wise, S., Yuen, E., Chan, C. et al. Effects of Chronic Renal Failure on the Pharmacokinetics of Ruboxistaurin and its Active Metabolite 338522. Clin Pharmacokinet 45, 297–303 (2006). https://doi.org/10.2165/00003088-200645030-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200645030-00005